Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

NCT02478320 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
12
Enrollment
OTHER
Sponsor class

Stopped Study terminated due to company's decision to discontinue drug development

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center

Collaborators